CA nanoparticles have also demonstrated the ability to reduce inflammation and apoptosis in acute hepatitis models by decreasing levels of TNF-α, IL-1β, and IL-18, as well as inhibiting NF-κB, NLRP3, and caspase-1, while promoting Bcl-2 levels [32]. This evidence concerns the gene IL18 and Acute hepatitis.